A distinct dexamethasone-dependent gene expression profile in the lungs of COVID-19 patients
Research output: Contribution to journal › Journal article › Research › peer-review
The effects of dexamethasone (DXM) treatment on pulmonary immunity in COVID-19 associated acute respiratory distress syndrome (CARDS) remain insufficiently understood. We performed transcriptomic RNA-seq analysis of bronchoalveolar lavage fluid from 20 mechanically ventilated patients: 12 with CARDS (DXM+ or DXM-) and 8 non-COVID-19 critically ill controls. CARDS (+DXM) was characterized by upregulation of genes related to B-cell and complement pathway activation, antigen presentation, phagocytosis and FC-gamma receptor signalling. Most ISGs were upregulated in CARDS, particularly in CARDS (-DXM). In conclusion, DXM treatment was not associated with regulation of pro-inflammatory pathways in CARDS but with regulation of other local immune responses.
Original language | English |
---|---|
Journal | The Journal of Infectious Diseases |
Volume | 226 |
Issue number | 12 |
Pages (from-to) | 2137–2141 |
ISSN | 0022-1899 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America and HIV Medicine Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213855/pdf/jiac218.pdf
Final published version
ID: 308832711